Glycogen storage in multiple muscles of old GSD-II mice can be rapidly cleared after a single intravenous injection with a modified adenoviral vector expressing hGAA

This publication has 25 references indexed in Scilit:

• Efficacy of Gene Therapy for a Prototypical Lysosomal Storage Disease (GSD-II) Is Critically Dependent on Vector Dose, Transgene Promoter, and the Tissues Targeted for Vector Transduction
  Molecular Therapy, 2002
• Acid a-Glucosidase Deficiency (Glycogenosis Type II, Pompe Disease)
  Current Molecular Medicine, 2002
• Long-Term Efficacy after [E1^-, polymerase^-] Adenovirus-Mediated Transfer of Human Acid-α-Glucosidase Gene into Glycogen Storage Disease Type II Knockout Mice
  Human Gene Therapy, 2001
• Towards a molecular therapy for glycogen storage disease type II (Pompe disease)
  Molecular Medicine Today, 2000
• Frequency of glycogen storage disease type II in The Netherlands: implications for diagnosis and genetic counselling
  European Journal of Human Genetics, 1999
• Systemic correction of the muscle disorder glycogen storage disease type II after hepatic targeting of a modified adenovirus vector encoding human acid-α-glucosidase
  Proceedings of the National Academy of Sciences, 1999
• Clinical and metabolic correction of pompe disease by enzyme therapy in acid maltase-deficient quail.
  Journal of Clinical Investigation, 1998
• Glycogenosis type II (acid maltase deficiency)
  Muscle & Nerve, 1995
• Respiratory Insufficiency in Adult-Type Acid Maltase Deficiency
  Southern Medical Journal, 1993
• α-Glucosidase deficiency in generalized glycogen-storage disease (Pompe's disease)
  Biochemical Journal, 1963